Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Anasagasti Angulo, Lorenzo ^a   Garcia Vega, Yanelda ^b   Barcelona Perez, Silvia ^b   Lopez Saura, Pedro ^b   Bello Rivero, Iraldo ^b  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DIPHENHYDRAMINE; DIPYRONE; DOXORUBICIN; GAMMA INTERFERON; INTERFERON;

ABULIA; ADULT; ADVANCED CANCER; AGED; ALLERGIC RHINITIS; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BASAL CELL SKIN CARCINOMA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SIZE; CHEMOSIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ERYTHEMA; EYE PAIN; FEMALE; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; OTALGIA; PAIN; PERIPHERAL EDEMA; PLEXUS BRACHIAL PAIN; POWERLESSNESS; RISK REDUCTION; SEPSIS; SIDE EFFECT; SKIN CARCINOMA; SKIN SURGERY; SQUAMOUS CELL SKIN CARCINOMA; SWEATING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BASAL CELL CARCINOMA; BAYES THEOREM; DRUG RESISTANCE; METHODOLOGY; MIDDLE AGED; ONCOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; BAYES THEOREM; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERONS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 68949203682     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-262     Document Type: Article

References (60)

1. Wong CS Strange RC Lear JT Basal cell carcinoma BMJ 2003, 327:794-798 10.1136/bmj.327.7418.794 214105 14525881
2. Oram Y Orengo Y Alford E Grean LK Netscher DT Basal cell carcinoma of the scalp resulting in spine metastasis in black patients J Am Acad Dermatol 1994, 31:916-920 10.1016/S0190-9622(94)70259-4 7962748
3. Skelton LA The effective treatment of basal cell carcinoma Br J Nurs 2009, 18:348-350
4. Baron ED Stevens SR Sunscreens and immune protection Br J Dermatol 2002, 146:933-937 10.1046/j.1365-2133.2002.04844.x 12072058
5. Gaspari AA Sauder DN Immunotherapy of Basal Cell Carcinoma: Evolving Approaches Dermatol Surg 2003, 29:1027-1034 10.1046/ j.1524-4725.2003.29295.x 12974699
6. Chu CY Cha ST Lin WC Lu PH Tan CT Chang CC Lin BR Jee SH Kuo ML Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/interleukin-6 pathway Carcinogenesis 2009, 30:205-213 10.1093/carcin/bgn228 18849299
7. Skin Cancer Keyvan Nouri MD McGraw Hill 2007
8. Hutchin ME Kariapper MS Grachtchouk M Wang A Wei L Cummings D Liu J Michael LE Glick A Dlugosz AA Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: Conditional skin tumorigenesis recapitulates the hair growth cycle Genes Dev 2005, 19:214-223 10.1101/gad.1258705 545881 15625189
9. Rohrbach JM Stiemer R Mayer A Riedinger C Duijvestijn A Zierhut M Immunology and growth characteristics of ocular basal cell carcinoma Graefe's Arch Clin Exp Ophthalmol 2001, 239:35-40 10.1007/s004170000221
10. Buechner A Stanislaw Wernli Marion Harr Thomas Hahn Sinuhe Itin Peter Erb Peter Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide J Clin Invest 1997, 100:2691-2696 10.1172/ JCI119814 508472 9389732
11. Walling OW Fosko W Scott Geraminejad A Pedram Whitaker C Duane Arpey J Christopher Aggressive basal cell carcinoma: Presentation, pathogenesis, and management Cancer and Metastasis Reviews 2004, 23:389-402 10.1023/ B:CANC.0000031775.04618.30 15197337
12. D Gross N Monroe M Skin Cancer: Squamous Cell Carcinoma http://emedicine.medscape.com
13. Bauman JE Eaton KD Martins RG Treatment of recurrent squamous cell carcinoma of the skin with cetuximab Arch Dermatol 2007, 143:889-892 10.1001/archderm.143.7.889 17638733
14. Cornell RC Greenway HT Tucker SB Edwards L Ashworth S Vance JC Tanner DJ Taylor EL Smiles KA Peets EA Intralesional interferon therapy for basal cell carcinoma J Am Acad Dermatol 1990, 23:694-700 10.1016/ 0190-9622(90)70276-N 2229497
15. Edwards L Berman B Rapini RP Whiting DA Tyring S Greenway HT Jr Eyre SP Tanner DJ Taylor EL Peets E Smiles KA Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy Arch Dermatol 1992, 128:1486-1489 10.1001/archderm.128.11.1486 1444502
16. Kim K Yavel R Gross V Brody N Intralesional interferon a-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: Revisited Dermatologic Surgery 2004, 30:116-120 10.1111/j.1524-4725.2004.30020.x 14692941
17. Tucker S Polasek J Perri A Goldsmith E Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy J Am Acad Dermatol 2006, 54:1033-1038 10.1016/j.jaad.2006.02.035 16713458
18. Stenquist B Wennberg A Gisslen H Larko O Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery J Am Acad Dermatol 1992, 27:65-69 10.1016/ 0190-9622(92)70158-C 1619079
19. Brewster AM Lee JJ Clayman GL Clifford JL Reyes MJ Zhou X Sabichi AL Strom SS Collins R Meyers CA Lippman SM Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma J Clin Oncol 2007, 25:1974-1978 10.1200/ JCO.2006.05.9873 17513803
20. Levy DE Lew DJ Decker T Kessler DS Darnell JE Jr Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3 EMBO J 1990, 9:1105-1111 551785 2108862
21. Quesada JR Toxicity and side effects of interferons Interferons principles and medical applications The University of Texas Medical Branch at Galveston, Texas Baron S, Coppenhaver DH, Dianzani F 1992:427-432
22. Vial T Descotes J Clinical toxicity of the interferons Drug safety 1994, 10:115-150 10.2165/00002018-199410020-00003 7516663
23. Gogas H Ioannovich J Dafni U Stavropoulou-Giokas C Frangia K Tsoutsos D Panagiotou P Polyzos A Papadopoulos O Stratigos A Markopoulos C Bafaloukos D Pectasides D Fountzilas G Kirkwood JM Prognostic Signficance of Autoimmunity during treatment of Melanoma with Interferon NEJM 2006, 16:709-718 10.1056/NEJMoa053007
24. Calvert AH Newell DR Gumbrell LA O'Reilly S Burnell M Boxall FE Siddik ZH Judson IR Gore ME Wiltshaw E Carboplatin dosage: Prospective evaluation of a single formula based on renal function J Clin Oncol 1989, 7:1748-1756 2681557
25. Sociedad Argentina de Dermatología Consenso sobre Carcinoma Basocelular Carcinoma Espinocelular Guía de Recomendaciones 2005 http://www.sad.org.ar/revista/pdf/ 10.1038/modpathol.3800512
26. Crowson N Basal Cell Carcinoma: Biology, morphology and clinical implications Modern Pathology 2006, 19:S127-S147 10.1023/ B:CANC.0000031775.04618.30 16446711
27. Walling HW Fosko SW Geraminejad PA Whitaker DC Arpey CJ Aggressive basal cell carcinoma: Presentation, pathogenesis, and management Cancer Metastasis Rev 2004, 23:389-402 10.1023/B:CANC.0000031775.04618.30 15197337
28. Anuario Estadístico de Salud Ministerio de Salud Pública Dirección Nacional de Estadística 2004 http://www.cigb.edu.cu/
29. Neudorfer M Merimsky O Lazar M Geyer O Cisplatin and doxorubicin for invasive basal cell carcinoma of the eyelids Ann Ophthalmol 1993, 25:11-13 10.1007/BF00159865 8427483
30. Amoaku WM Bagegni A Logan WC Archer DB Orbital infiltration by eyelid skin carcinoma Int Ophthalmol 1990, 14:285-294 10.1016/ j.ophtha.2004.11.036 2370130
31. Leibovitch I McNab A Sullivan T Davis G Selva D Orbital invasion by periocular basal cell carcinoma Ophthalmology 2005, 112:717-723 10.1016/ 0190-9622(92)70158-C 15808267
32. Stenquist B Wennberg A Gisslen H Larko O Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery J Am Acad Dermatol 1992, 27:65-69 10.1016/ 0190-9622(92)70158-C 1619079
33. Kowalzick L Rogozinski T Wimheuer R Pilz J Manske U Scholz A Fierlbeck G Mohr P Ochsendorf F Wagner G Gaus W Brzoska J Jablonska S Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: Results of an open-label multicentre study Eur J Dermatol 2002, 12:558-561 10.2165/00003495-199550010-00005 12459527
34. Marks R Motley RJ Skin cancer. Recognition and treatment Drugs 1995, 50:48-61 10.1007/s00432-004-0656-6 7588089
35. Wollina U Hansel G Koch A Köstler E Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin J Cancer Res Clin Oncol 2005, 131:300-304 10.1034/ j.1600-0420.2002.800623_3.x 15619125
36. Fenton S Kennedy S Moriarty P The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids Acta Ophthalmologica Scandinavica 2002, 80:674-675 10.1080/028418699431203 12485296
37. Roth AD Morant R Alberto P High Dose Etretinate and Interferon-alpha: A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas Acta Oncol 1999, 38:613-618 10.1080/028418699431203 10427950
38. Ernstoff M Nair S Bahnson R Miketic L Banner B Gooding W Day R Whiteside T Hakala T Kirkwood JM A phase IA trial of sequential administration recombinant DNA-produced interferons: Combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma JCO 1990, 1:1637-1649
39. Novelli F Allione A Bernabei P Rigamonti L Forni G Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells Cancer Detect Prev 1997, 21:191-195 9101080
40. Johnsen JI Pettersen I Ponthan F Sveinbjornsson B Flaegstad T Kogner P Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL Int J Oncol 2004, 25:1849-1857 10.1007/BF01740941 15547726
41. de Mulder PHM Debruyne FMJ Franssen MPH Geboers ADH Strijk S Reintjes Ad GM Doesburg WH Damsma O Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma Cancer Immunol Immunother 1990, 31:321-324 10.1007/BF01740941 2115817
42. Tong HX Lu CW Zhang JH Ma L Zhang JH Combination of gamma-interferon with trail and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y Chin Med Sci J 2007, 22:38-43 10.1097/ CJI.0b013e3181818769 17441316
43. Zhu Y Tibensky I Schmidt J Ryschich E Märten A Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma J Immunother 2008, 31:599-606 10.1097/ CJI.0b013e318157c682 18600184
44. Zhu Y Tibensky I Schmidt J Hackert T Ryschich E Jäger D Büchler MW Märten A Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma J Immunother 2008, 31:28-33 10.1097/ CJI.0b013e318157c682 18157009
45. Guthrie TH Jr Porubsky ES Luxenberg MN Shah KJ Wurtz KL Watson PR Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy J Clin Oncol 1990, 8:342-346 10.1001/ archderm.126.12.1660 2405109
46. Khandekar JD Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: A report on two patients (letter) Arch Dermatol 1990, 126:1660 10.1016/0190-9622(91)70108-E 2256701
47. Lo JS Snow SN Reizner GT Mohs FE Larson PO Hruza GJ Metastatic basal cell carcinoma: Report of twelve cases with a review of the literature J Am Acad Dermatol 1991, 24:715-719 10.1016/0190-9622(91)70108-E 1869642
48. Rowe DE Carroll RJ Day CL Jr Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: Implications for patient follow-up J Dermatol Surg Oncol 1989, 15:315-328 10.1016/ S0733-8635(05)70020-6 2646336
49. Stadler R Interferons in dermatology. Present-day standard Dermatol Clin 1998, 16:377-398 10.1093/jnci/84.4.235 9589211
50. Lippman SM Donovan DT Frankenthaler RA Weber RS Earley CL Hong WK Goepfert H 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin J Natl Cancer Inst 1992, 84:235-241 10.1200/JCO.2006.05.9873 1734084
51. Brewster AM Lee JJ Clayman GL Clifford JL Reyes MJ Zhou X Sabichi AL Strom SS Collins R Meyers CA Lippman SM Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma J Clin Oncol 2007, 25:1974-1978 10.1200/ JCO.2006.05.9873 17513803
52. Hui JL Kluger MS Madge LA Lian Z Bothwell ALM Pober JS Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis Am J Path 2002, 161:1485-1495 1867313 12368221
53. Sypniewski D Bednarek I Ga ka S Loch T Machnik G Influence of interferon-alpha and ribavirin on the transcription of interferon-gamma and IFN-gamma receptor genes in Jurkat cells Acta Pol Pharm 2008, 65:345-351 10.1126/science.288.5475.2357 18646554
54. Takaoka A Mitani Y Suemori H Sato M Yokochi T Shigeru Tanaka N Taniguchi T Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains Science 2000, 30:2357-2360 10.1126/science.288.5475.2357
55. Slaton JW Perrotte P Inoue K Dinney CP Fidler IJ Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule Clin Cancer Res 1999, 5:2726-2734 10537335
56. Fathallah-Shaykh HM Zhao LJ Kafrouni AI Smith GM Forman J Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis J Immunol 2000, 164:217-222 10.1158/ 1078-0432.CCR-04-1470 10605014
57. Katayama A Ogino T Bandoh N Nonaka S Harabuchi Y Expression of CXCR4 and Its Down-Regulation by IFN-γ in Head and Neck Squamous Cell Carcinoma Clin Cancer Res 2005, 11:2937-2946 10.1038/nrc1782 15837745
58. de Visser KE Eichten A Coussens LM Paradoxical Roles of the Immune System During Cancer Development Nat Rev Cancer 2006, 6:24-37 10.1038/ nrc1782 16397525
59. Brown JL Barsoum J Qin XQ CD4+ T Helper Cell-Independent Antitumor Response Mediated by Murine IFN-β Gene Delivery in Immunocompetent Mice Journal of Interferon & Cytokine Research 2002, 22:719-728 10.1089/10799900260100222
60. Belardellia F Ferrantinia M Proiettia E Kirkwoodb JM Interferon-alpha in tumor immunity and immunotherapy Cytokine and growth factor 2002, 13:119-134 10.1016/S1359-6101(01)00022-3